Texas Permanent School Fund Corp Buys 32,047 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Texas Permanent School Fund Corp grew its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 9.9% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 357,396 shares of the company’s stock after purchasing an additional 32,047 shares during the period. Texas Permanent School Fund Corp’s holdings in Teva Pharmaceutical Industries were worth $5,990,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Harel Insurance Investments & Financial Services Ltd. raised its holdings in Teva Pharmaceutical Industries by 51.4% during the 2nd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 33,390,327 shares of the company’s stock valued at $559,622,000 after buying an additional 11,334,780 shares during the period. Menora Mivtachim Holdings LTD. increased its position in Teva Pharmaceutical Industries by 31.9% during the second quarter. Menora Mivtachim Holdings LTD. now owns 38,493,294 shares of the company’s stock valued at $645,148,000 after acquiring an additional 9,303,978 shares during the last quarter. Phoenix Financial Ltd. increased its position in Teva Pharmaceutical Industries by 31.7% during the second quarter. Phoenix Financial Ltd. now owns 37,761,444 shares of the company’s stock valued at $632,882,000 after acquiring an additional 9,094,372 shares during the last quarter. Soundwatch Capital LLC purchased a new stake in shares of Teva Pharmaceutical Industries in the second quarter valued at $143,533,000. Finally, Maverick Capital Ltd. lifted its holdings in shares of Teva Pharmaceutical Industries by 14,351.6% in the 2nd quarter. Maverick Capital Ltd. now owns 4,377,690 shares of the company’s stock worth $73,370,000 after acquiring an additional 4,347,398 shares during the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Down 0.1%

Shares of NYSE:TEVA opened at $30.11 on Wednesday. Teva Pharmaceutical Industries Ltd. has a 52-week low of $12.47 and a 52-week high of $30.44. The stock has a market cap of $34.53 billion, a P/E ratio of 50.18, a price-to-earnings-growth ratio of 1.79 and a beta of 0.67. The business’s 50 day moving average is $23.83 and its 200 day moving average is $19.81. The company has a quick ratio of 0.82, a current ratio of 1.11 and a debt-to-equity ratio of 2.31.

Wall Street Analysts Forecast Growth

TEVA has been the topic of several analyst reports. Barclays assumed coverage on shares of Teva Pharmaceutical Industries in a report on Tuesday, December 9th. They set an “overweight” rating and a $35.00 price target on the stock. JPMorgan Chase & Co. boosted their target price on Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the company an “overweight” rating in a research report on Tuesday. Scotiabank started coverage on Teva Pharmaceutical Industries in a research note on Friday, December 5th. They set a “sector outperform” rating and a $35.00 target price on the stock. Bank of America raised their price target on Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. Finally, The Goldman Sachs Group boosted their price objective on Teva Pharmaceutical Industries from $28.00 to $31.00 and gave the company a “buy” rating in a report on Monday, December 8th. Three analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $31.13.

Insider Activity at Teva Pharmaceutical Industries

In related news, Director Roberto Mignone sold 200,000 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $24.11, for a total transaction of $4,822,000.00. Following the transaction, the director directly owned 495,000 shares of the company’s stock, valued at $11,934,450. This trade represents a 28.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, VP Richard Daniell sold 115,468 shares of the business’s stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $28.68, for a total transaction of $3,311,622.24. Following the completion of the transaction, the vice president directly owned 48,384 shares of the company’s stock, valued at $1,387,653.12. This trade represents a 70.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 532,360 shares of company stock worth $14,364,929 over the last three months. 0.55% of the stock is owned by corporate insiders.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.